Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Coya Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.13) per share for the year, up from their previous estimate of ($1.38). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Coya Therapeutics' Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.68) EPS.
Separately, Chardan Capital reissued a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, November 7th.
View Our Latest Stock Report on COYA
Coya Therapeutics Stock Down 2.2 %
Coya Therapeutics stock traded down $0.16 during midday trading on Thursday, hitting $7.08. The company's stock had a trading volume of 68,134 shares, compared to its average volume of 71,625. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.69. The company has a market capitalization of $118.31 million, a PE ratio of -11.14 and a beta of 0.46. The stock's 50-day moving average price is $7.10 and its 200-day moving average price is $7.02.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.15.
Insider Activity at Coya Therapeutics
In other Coya Therapeutics news, CEO Arun Swaminathan bought 5,000 shares of Coya Therapeutics stock in a transaction on Monday, November 11th. The stock was purchased at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the purchase, the chief executive officer now directly owns 5,000 shares of the company's stock, valued at $36,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.00% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in COYA. Gilbert & Cook Inc. bought a new stake in shares of Coya Therapeutics during the 2nd quarter worth $61,000. Renaissance Technologies LLC bought a new position in Coya Therapeutics during the second quarter valued at about $101,000. GHP Investment Advisors Inc. acquired a new position in shares of Coya Therapeutics in the third quarter valued at $169,000. Finally, Vanguard Group Inc. boosted its stake in Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company's stock worth $8,407,000 after buying an additional 750,338 shares in the last quarter. 39.75% of the stock is owned by institutional investors.
Coya Therapeutics Company Profile
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
See Also
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.